Author: mercia1

Profile picture of mercia1
Website
http://www.mercia.co.uk

Posts by mercia1

Biotecnol and PolyTherics enter into a Research Collaboration for the Development of Tribody Antibody Drug Conjugates

Posted on

North Brunswick, NJ and London, UK – 23 October 2012. Biotecnol, Inc. and PolyTherics Ltd. have entered into a collaboration for the development of multi-specific Tribody Drug Conjugates (TDCs). The companies will combine Biotecnol’s Tribody technology with PolyTherics’ proprietary site-specific linker technologies to attach cytotoxic payloads to various Tribodies for targeted cancer therapy. Tribody molecules

PolyTherics expands collaboration with a top five pharmaceutical company to enhance the clinical properties of biopharmaceuticals using PolyPEG

Posted on

London, UK, 15 th October 2012 – PolyTherics Limited (“PolyTherics”), a provider of solutions to enable the development of better biopharmaceuticals, has extended its collaboration with a top five pharmaceutical company to further investigate applications of PolyTherics’ polymer, PolyPEG®. PolyPEG™ is a patented polymer designed to extend the half-life in the body of therapeutic proteins

Talking university spin-outs – University of Warwick

Posted on

Mark Payton, managing director of Mercia Fund Management, talks university spin- outs and looks at successful companies from the University of Warwick.Working with eight Midlands’ universities, Mercia Fund Management has supported spin- outs from seed to successful exit through investment, sourcing the right people to manage the funded company, and providing strategic input. This article

Psioxus Launches Phase I/II Clinical Trial Of Oncolytic Vaccine With Dosing Of Patient With Metastatic Colorectal Cancer

Posted on

‘Evolve’ Study Will Assess Safety and Tolerability of Unique Anti-Cancer Agent, ColoAd1 OXFORD, UK – 26 September 2012 – PsiOxus Therapeutics, Ltd. (PsiOxus) has treated the first patient in its phase I/II clinical trial of ColoAd1 for the treatment of metastatic solid tumours. The Evolve (EValuating OncoLytic Vaccine Efficacy) study is the first clinical trial

Pro Bono Bio obtains exclusive licence from PolyTherics

Posted on

London/Moscow, 10th September 2012 – Pro Bono Bio Group plc (“PBB”), the international healthcare group, and PolyTherics Limited (“PolyTherics”), a provider of solutions for the development of better biopharmaceuticals, announce further progress on their haematology alliance to produce longer-acting versions of blood factor proteins. Following an agreement between the parties in May 2012, PBB and

Looking at university spin-outs: University of Birmingham

Posted on

Founded in a hot bed of fresh thinking and unique ideas, university spin-outs are becoming increasingly popular with both savvy investors, who can achieve a healthy return, and universities benefitting from funding channelled back into their R&D and facilities. Working with eight Midlands’ universities, Mercia Fund Management has supported spin-outs from seed to successful exit

PolyTherics appoints new head of business development

Posted on

PRESS RELEASE London, UK, 20 August 2012 ? PolyTherics Limited (“PolyTherics”), a provider of solutions to enable the development of better biopharmaceuticals, is very pleased to announce the appointment of Dr Georg Buchner as Vice President of Business Development. Georg will work with Jenny Filbey, PolyTherics’ business development representative in the USA and CEO John